Case-control study of markers of insulin resistance and endometrial cancer risk

Endocrine-Related Cancer

Volumn 19, Issue 6, 2012, Pages 785-792

  Friedenreich, Christine M ^a,b   Langley, Annie R ^a   Speidel, Thomas P ^a   Lau, David C W ^b   Courneya, Kerry S ^c   Csizmadi, Ilona ^a,b   Magliocco, Anthony M ^d   Yasui, Yutaka ^c   Cook, Linda S ^a,b,e  

^a ALBERTA HEALTH SERVICES   (Canada)

^b UNIVERSITY OF CALGARY   (Canada)

^c UNIVERSITY OF ALBERTA   (Canada)

^d H LEE MOFFITT CANCER CENTER AND RESEARCH INSTITUTE   (United States)

^e UNIVERSITY OF NEW MEXICO SCHOOL OF MEDICINE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ADIPONECTIN; GLUCOSE; INSULIN; LEPTIN;

ADULT; ANTHROPOMETRY; ARTICLE; BLOOD SAMPLING; CANCER RISK; CASE CONTROL STUDY; CONTROLLED STUDY; ENDOMETRIUM CANCER; FEMALE; FLUOROMETRY; GLUCOSE BLOOD LEVEL; HUMAN; IMMUNOASSAY; INSULIN RESISTANCE; MAJOR CLINICAL STUDY; QUESTIONNAIRE;

ADIPONECTIN; AGED; BIOLOGICAL MARKERS; BLOOD GLUCOSE; CASE-CONTROL STUDIES; ENDOMETRIAL NEOPLASMS; FEMALE; HUMANS; INSULIN; INSULIN RESISTANCE; LEPTIN; MIDDLE AGED; RISK;

EID: 84869204248     PISSN: 13510088     EISSN: 14796821     Source Type: Journal    
DOI: 10.1530/ERC-12-0211     Document Type: Article

References (34)

1. Ashizawa N, Yahata T, Quan J, Adachi S, Yoshihara K & Tanaka K 2010 Serum leptin-adiponectin ratio and endometrial cancer risk in postmenopausal female subjects. Gynecologic Oncology 119 65-69. (doi:10.1016/j.ygyno.2010.07. 007)
2. Belfiorni A & Malaguarnera R 2011 Insulin receptor and cancer. Endocrine-Related Cancer 18 R125-R147. (doi:10.1530/ERC-11-0074)
3. Breslow N 1982 Design and analysis of case-control studies. Annual Review of Public Health 3 29-54. (doi:10.1146/annurev.pu.03.050182.000333)
4. Chu NF, Spiegelman D, Hotamisligil GS, Rifai N, Stampfer M & Rimm EB 2001 Plasma insulin, leptin, and soluble TNF receptors levels in relation to obesity-related atherogenic and thrombogenic cardiovascular disease risk factors among men. Atherosclerosis 157 495-503. (doi:10.1016/S0021-9150(00)00755-3)
5. Cleveland WS 1979 Robust locally weighted regression and smoothing scatterplots. Journal of the American Statistical Association 74 829-836. (doi:10.1080/01621459.1979.10481038)
6. Cust AE, Kaaks R, Friedenreich C, Bonnet F, Laville M, Lukanova A, Rinaldi S, Dossus L, Slimani N, Lundin E et al. 2007 Plasma adiponectin levels and endometrial cancer risk in pre- and postmenopausal women. Journal of Clinical Endocrinology and Metabolism 92 255-263. (doi:10.1210/jc.2006-1371)
7. DalMaso L,Augustin LS, KaralisA, TalaminiR, Franceschi S, Trichopoulos D, Mantzoros CS & La Vecchia C 2004 Circulating adiponectin and endometrial cancer risk. Journal of Clinical Endocrinology and Metabolism 89 1160-1163. (doi:10.1210/jc.2003-031716)
8. Efron B & Tibshirani R 1994 An Introduction to the Bootstrap. New York: Chapman & Hall/CRC.
9. Finucane FM, Luan J, Wareham NJ, Sharp SJ, O'Rahilly S, Balkau B, Flyvbjerg A, Walker M, Hojlund K, Nolan JJ et al. 2009 Correlation of the leptin:adiponectin ratio with measures of insulin resistance in non-diabetic individuals. Diabetologia 52 2345-2349. (doi:10.1007/s00125-009-1508-3)
10. Friedenreich CM, Cook LS, Magliocco AM, Duggan MA & Courneya KS 2010 Case-control study of lifetime total physical activity and endometrial cancer risk. Cancer Causes & Control 21 1105-1116. (doi:10.1007/s10552-010-9538-1)
11. Gallagher EJ & LeRoith D 2010 Insulin, insulin resistance, obesity, and cancer. Current Diabetes Reports 10 93-100. (doi:10.1007/s11892-010-0101-y)
12. Gnacińska M, Małgorzewicz S, Stojek M, Łysiak- Szydłowska W & Sworczak K 2009 Role of adipokines in complications related to obesity: a review. Advances in Medical Sciences 54 150-157. (doi:10.2478/v10039-009-0035-2)
13. Godsland IF 2010 Insulin resistance and hyperinsulinaemia in the development and progression of cancer. Clinical Science 118 315-332. (doi:10.1042/CS20090399)
14. Greenland S 1989 Modeling and variable selection in epidemiologic analysis. American Journal of Public Health 79 340-349. (doi:10.2105/AJPH.79.3. 340)
15. Guadagni F, Roselli M, Martini F, Spila A, Riondino S, D'Alessandro R, Del Monte G, Formica V, Laudisi A, Portarena I et al. 2009 Prognostic significance of serum adipokine levels in colorectal cancer patients. Anticancer Research 29 3321-3327.
16. Gunter MJ, Hoover DR, Yu H, Wassertheil-Smoller S, Manson JE, Li J, Harris TG, Rohan TE, Xue X, Ho GY et al. 2008 A prospective evaluation of insulin and insulin-like growth factor-I as risk factors for endometrial cancer. Cancer Epidemiology, Biomarkers & Prevention 17 921-929. (doi:10.1158/1055-9965.EPI-07-2686)
17. Harrell FE 2001 Regression Modeling Strategies: with Applications to Linear Models, Logistic Regression, and Survival Analysis. New York: Springer.
18. Hosmer DWLS 2000 Applied Logistic Regression. New York: Wiley.
19. Kaaks R, Lukanova A & Kurzer MS 2002 Obesity, endogenous hormones, and endometrial cancer risk: a synthetic review. Cancer Epidemiology, Biomarkers & Prevention 11 1531-1543. (Pubitemid 36020003)
20. Kehlet H 2000 Manipulation of the metabolic response in clinical practice. World Journal of Surgery 24 690-695. (doi:10.1007/s002689910111)
21. Lasalandra C, Coviello M, Falco G, Divella R, Trojano G, Laterza AM, Quero C, Pepe V, Zito FA & Quaranta M 2010 Serum vascular endothelial growth factor and adiponectin levels in patients with benign and malignant gynecological diseases. International Journal of Gynecological Cancer 20 507-512. (doi:10.1111/IGC.0b013e3181c54fc5)
22. Li H, Stampfer MJ, Mucci L, Rifai N, Qiu W, Kurth T & Ma J 2010 A 25-year prospective study of plasma adiponectin and leptin concentrations and prostate cancer risk and survival. Clinical Chemistry 56 34-43. (doi:10.1373/clinchem.2009.133272)
23. Lihn AS, Pedersen SB & Richelsen B 2005 Adiponectin: action, regulation and association to insulin sensitivity. Obesity Reviews 6 13-21. (doi:10.1111/j.1467-789X.2005.00159.x)
24. Nagamani M & Stuart CA 1998 Specific binding and growth-promoting activity of insulin in endometrial cancer cells in culture. American Journal of Obstetrics and Gynecology 179 6-12. (doi:10.1016/S0002-9378(98)70244-3)
25. Oda N, Imamura S, Fujita T, Uchida Y, Inagaki K, Kakizawa H, Hayakawa N, Suzuki A, Takeda J, Horikawa Y et al. 2008 The ratio of leptin to adiponectin can be used as an index of insulin resistance. Metabolism 57 268-273. (doi:10.1016/j.metabol.2007.09.011)
26. Petridou E, Mantzoros C, Dessypris N, Koukoulomatis P, Addy C, Voulgaris Z, Chrousos G & Trichopoulos D 2003 Plasma adiponectin concentrations in relation to endometrial cancer: a case-control study in Greece. Journal of Clinical Endocrinology and Metabolism 88 993-997. (doi:10.1210/jc.2002-021209)
27. Pischon T, Hotamisligil GS & Rimm EB 2003 Adiponectin: stability in plasma over 36 h and within-person variation over 1 year. Clinical Chemistry 49 650-652. (doi:10.1373/49.4.650)
28. Renehan AG & Berster JM 2008 Insulin and Cancer: Report of the Proceedings of the First International Workshop, October 27-28, 2007, Dusseldorf, Germany. Pediatric Endocrinology Reviews 5 810-816. (Pubitemid 351462147)
29. Sarafidis PA, Lasaridis AN, Nilsson PM, Pikilidou MI, Stafilas PC, Kanaki A, Kazakos K, Yovos J & Bakris GL 2007 Validity and reproducibility of HOMA-IR, 1/HOMA-IR, QUICKI and McAuley's indices in patients with hypertension and type II diabetes. Journal of Human Hypertension 21 709-716. (doi:10.1038/sj.jhh.1002201)
30. Soliman PT, Cui X, Zhang Q, Hankinson SE & Lu KH 2011 Circulating adiponectin levels and risk of endometrial cancer: the prospective Nurses' Health Study. American Journal of Obstetrics and Gynecology 167 e161-e165. (doi:10.1016/j.ajog.2010.08.045)
31. Tworoger SS, Eliassen AH, Kelesidis T, Colditz GA, Willett WC, Mantzoros CS & Hankinson SE 2007 Plasma adiponectin concentrations and risk of incident breast cancer. Journal of Clinical Endocrinology and Metabolism 92 1510-1516. (doi:10.1210/jc.2006-1975)
32. Waksberg J 1978 Sampling methods for random digit dialing. Journal of the American Statistical Society 73 40-46.
33. Weiderpass E, Brismar K, Bellocco R, Vainio H & Kaaks R 2003 Serum levels of insulin-like growth factor-I, IGF-binding protein 1 and 3, and insulin and endometrial cancer risk. British Journal of Cancer 89 1697-1704. (doi:10.1038/sj.bjc.6601312)
34. Wu MH, Chou YC, Chou WY, Hsu GC, Chu CH, Yu CP, Yu JC & Sun CA 2009 Circulating levels of leptin, adiposity and breast cancer risk. British Journal of Cancer 100 578-582. (doi:10.1038/sj.bjc.6604913)